CN103534255B - 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶 - Google Patents

作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶 Download PDF

Info

Publication number
CN103534255B
CN103534255B CN201180066859.7A CN201180066859A CN103534255B CN 103534255 B CN103534255 B CN 103534255B CN 201180066859 A CN201180066859 A CN 201180066859A CN 103534255 B CN103534255 B CN 103534255B
Authority
CN
China
Prior art keywords
pyrimidine
carboxamide
alkyl
difluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180066859.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103534255A (zh
Inventor
胡安·乔斯·马鲁甘
诺埃尔·索撒尔
埃胡德·戈尔金
伟·郑
S·帕特奈克
艾伦·西德兰斯基
奥米德·莫塔巴尔
文迪·韦斯特布鲁克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN103534255A publication Critical patent/CN103534255A/zh
Application granted granted Critical
Publication of CN103534255B publication Critical patent/CN103534255B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201180066859.7A 2010-12-08 2011-12-08 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶 Active CN103534255B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42094610P 2010-12-08 2010-12-08
US61/420,946 2010-12-08
PCT/US2011/063928 WO2012078855A1 (en) 2010-12-08 2011-12-08 Substituted pyrazolopyrimidines as glucocerebrosidase activators

Publications (2)

Publication Number Publication Date
CN103534255A CN103534255A (zh) 2014-01-22
CN103534255B true CN103534255B (zh) 2016-12-21

Family

ID=45498099

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180066859.7A Active CN103534255B (zh) 2010-12-08 2011-12-08 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶

Country Status (24)

Country Link
US (3) US9353117B2 (enExample)
EP (2) EP2649075B1 (enExample)
JP (1) JP6154746B2 (enExample)
KR (1) KR101931224B1 (enExample)
CN (1) CN103534255B (enExample)
AU (1) AU2011338377B2 (enExample)
BR (1) BR112013014242B1 (enExample)
CA (1) CA2820362C (enExample)
CY (1) CY1125186T1 (enExample)
DK (2) DK2649075T3 (enExample)
ES (2) ES2912284T3 (enExample)
HR (1) HRP20220512T1 (enExample)
HU (1) HUE038635T2 (enExample)
IL (2) IL226767B (enExample)
LT (1) LT3366688T (enExample)
MX (2) MX354506B (enExample)
PL (2) PL3366688T3 (enExample)
PT (2) PT2649075T (enExample)
RS (1) RS63320B1 (enExample)
RU (1) RU2603637C2 (enExample)
SI (2) SI2649075T1 (enExample)
TR (1) TR201810523T4 (enExample)
WO (1) WO2012078855A1 (enExample)
ZA (1) ZA201304215B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649075B1 (en) 2010-12-08 2018-04-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
CN103764166B (zh) * 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
EP2723717A2 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
EP2768509B1 (en) * 2011-10-20 2017-03-22 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2014089379A1 (en) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20170920A1 (es) 2014-11-03 2017-07-12 Bayer Pharma AG Piperidinilpirazolopirimidinonas y utilizacion de las mismas
HRP20240644T1 (hr) 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3317282B1 (en) 2015-07-01 2020-12-09 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US20190092789A1 (en) * 2015-09-04 2019-03-28 Lysosomal Therapeutics Inc. Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
EP3344625A4 (en) * 2015-09-04 2019-03-27 Lysosomal Therapeutics Inc. THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
EP3429590A4 (en) * 2016-03-16 2020-02-19 Lysosomal Therapeutics Inc. METHOD AND COMPOSITIONS FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE IN A SUBJECT CARRIING THE SPHINGOLIPIDOSIS GENE
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
JP7046827B2 (ja) * 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
SG11201808830YA (en) * 2016-04-06 2018-11-29 Lysosomal Therapeutics Inc Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
WO2017192929A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018083085A1 (en) * 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
JP7216705B2 (ja) * 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法
JP2020530000A (ja) 2017-08-02 2020-10-15 ノースウエスタン ユニバーシティ 置換縮合ピリミジン化合物およびその使用
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN
US11459325B2 (en) 2018-01-31 2022-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
JP7179161B2 (ja) 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体
AU2019356011B2 (en) 2018-10-05 2025-02-06 Forma Therapeutics, Inc. Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors
US11414431B2 (en) * 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
AR117177A1 (es) 2018-12-10 2021-07-14 Lilly Co Eli DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
JP7414965B2 (ja) * 2019-08-21 2024-01-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
WO2021055630A1 (en) 2019-09-17 2021-03-25 Bial- Biotech Investments, Inc. Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
WO2021055627A1 (en) 2019-09-17 2021-03-25 Bial- Biotech Investments, Inc. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
CN114787135A (zh) 2019-09-17 2022-07-22 比亚尔R&D投资股份公司 经取代的咪唑甲酰胺及其在治疗医学病症中的用途
JP2023503470A (ja) * 2019-11-25 2023-01-30 ゲイン セラピューティクス エスアー ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用
WO2021162944A1 (en) 2020-02-12 2021-08-19 Eli Lilly And Company Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089471A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
WO2006087120A2 (de) * 2005-02-17 2006-08-24 Bayer Cropscience Ag Pyrazolopyrimidine
WO2007048066A2 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2009152083A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284886A1 (en) 2002-10-21 2004-05-13 William E. Balch CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
BRPI0416216A (pt) 2003-11-12 2006-12-26 Amicus Therapeutics Inc composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina
US7488721B2 (en) 2004-05-13 2009-02-10 Mcmaster University Real time methylumbelliferone-based assay
WO2005113004A2 (en) 2004-05-14 2005-12-01 The Cleveland Clinic Founfation Small molecule inhibitors for mrp1 and other multidrug transporters
PL1761541T3 (pl) 2004-06-21 2008-06-30 Hoffmann La Roche Pochodne pirazolopirymidyny
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
EA013525B1 (ru) 2005-05-20 2010-06-30 Алантос-Фармасьютикалз Холдинг, Инк. Гетеробициклические ингибиторы металлопротеазы и их применение
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
ES2376642T3 (es) * 2005-08-15 2012-03-15 F. Hoffmann-La Roche Ag Derivados de piperidina y de piperazina como antagonistas del p2x3.
EP1945220A1 (en) * 2005-10-21 2008-07-23 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
WO2008054947A2 (en) 2006-10-02 2008-05-08 The Brigham And Women's Hospital, Inc. Structure of acid beta-glucosidase and methods for identifying therapeutic agents
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
AU2008240138B2 (en) 2007-04-13 2013-03-07 Amicus Therapeutics, Inc. Treatment of Gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers
WO2008134036A1 (en) 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES
ES2559859T3 (es) 2007-05-16 2016-02-16 The Brigham And Women's Hospital, Inc. Tratamiento de sinucleinopatías
WO2008154207A1 (en) 2007-06-08 2008-12-18 The Burnham Institute For Medical Research Methods and compounds for regulating apoptosis
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
WO2009049421A1 (en) 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2307440A4 (en) * 2008-07-01 2012-12-19 Zacharon Pharmaceuticals Inc HEPARAN SULFATE INHIBITORS
EP2649075B1 (en) * 2010-12-08 2018-04-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
HRP20240644T1 (hr) * 2014-11-06 2024-08-02 Bial-R&D Investments, S.A. Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089471A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
WO2006087120A2 (de) * 2005-02-17 2006-08-24 Bayer Cropscience Ag Pyrazolopyrimidine
WO2007048066A2 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2009152083A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
EP3366688B1 (en) 2022-02-09
IL226767B (en) 2018-06-28
ES2681218T3 (es) 2018-09-12
DK2649075T3 (en) 2018-07-30
ES2912284T3 (es) 2022-05-25
DK3366688T3 (da) 2022-05-02
CN103534255A (zh) 2014-01-22
SI2649075T1 (sl) 2018-10-30
EP2649075A1 (en) 2013-10-16
RU2013126094A (ru) 2015-01-20
KR101931224B1 (ko) 2018-12-20
JP6154746B2 (ja) 2017-06-28
KR20140010012A (ko) 2014-01-23
US9353117B2 (en) 2016-05-31
PL2649075T3 (pl) 2018-09-28
US20180263988A1 (en) 2018-09-20
RU2603637C2 (ru) 2016-11-27
EP3366688A1 (en) 2018-08-29
CY1125186T1 (el) 2024-12-13
US20140249145A1 (en) 2014-09-04
ZA201304215B (en) 2014-03-26
BR112013014242A2 (pt) 2018-06-26
RS63320B1 (sr) 2022-07-29
CA2820362A1 (en) 2012-06-14
WO2012078855A1 (en) 2012-06-14
US9974789B2 (en) 2018-05-22
MX385600B (es) 2025-03-18
AU2011338377A8 (en) 2015-10-29
IL259648A (en) 2018-07-31
HRP20220512T1 (hr) 2022-05-27
LT3366688T (lt) 2022-05-25
AU2011338377B2 (en) 2016-08-04
SI3366688T1 (sl) 2022-07-29
AU2011338377A1 (en) 2013-07-04
PL3366688T3 (pl) 2022-05-23
PT3366688T (pt) 2022-05-11
JP2013544893A (ja) 2013-12-19
HUE038635T2 (hu) 2018-11-28
US10925874B2 (en) 2021-02-23
US20160346284A1 (en) 2016-12-01
TR201810523T4 (tr) 2018-08-27
EP2649075B1 (en) 2018-04-25
BR112013014242B1 (pt) 2022-02-22
MX2013006462A (es) 2013-10-01
CA2820362C (en) 2020-03-24
MX354506B (es) 2018-01-16
IL259648B (en) 2021-03-25
PT2649075T (pt) 2018-07-30

Similar Documents

Publication Publication Date Title
CN103534255B (zh) 作为葡萄糖脑苷脂酶激活剂的取代的吡唑并嘧啶
US6825184B2 (en) 1,4-Disubstituted benzo-fused urea compounds
US9464035B2 (en) Salicylic acid derivatives useful as glucocerebrosidase activators
US6635647B2 (en) Decahydro-isoquinolines
US12473266B2 (en) Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
JP2018533594A (ja) 筋萎縮性側索硬化症を処置するための化合物
US11834424B2 (en) Compounds useful as chaperone-mediated autophagy modulators
TWI688565B (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
TW202416989A (zh) 作為pi3k抑制劑的苯并嘧啶-4(3h)-酮
CN109937039A (zh) 用于癌症治疗的双重clk/cdk1抑制剂
TW202404591A (zh) 作為pi3k抑制劑之苯并嘧啶-4(3h)-酮
KR20240155871A (ko) 소르틸린 의존성 질병의 치료를 위한 아미노산 기반 카바메이트 및/또는 요소
JP2023507180A (ja) Ｏｇａ阻害剤化合物
JP2020514284A (ja) イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用
JP2023512482A (ja) Ｆｇｆｒキナーゼ阻害剤としてのピリダジンおよび１，２，４－トリアジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant